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The genome of an organism has the complete set of biochemical instructions 
required for sustenance of life. Mutations or abnormalities in this genome lead to genetic 
disorders. Currently available therapeutic options mostly focus on treating the symptoms, 
but not curing them. Gene therapy promises to be a curative form of medicine. In gene 
therapy cells carrying a defective gene are targeted and replaced with a healthy copy of 
that gene. The vehicles used for delivering this gene are known as vectors. Retroviruses 
are popularly used gene therapy/transfer vectors. However, retroviruses are limited in the 
range of cells they can enter and infect. The range of cells targeted by the viral vector can 
be either expanded or narrowed by replacing the envelope of the virus with the envelope 
of another virus that has the desired range of tissue tropism. Such hybrid viruses are 
called pseudotyped viruses. Previously, we have pseudotyped Moloney Murine Leukemia 
Virus (MoMuLV), a retrovirus with the envelope of Ross River Virus (RRV), an 
alphavirus. Here, we substituted amino-acid residues of RR-envelope glycoprotein with 
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basic amino-acid residues. We show that this makes the pseudotyped virus utilize 
heparan sulfate, a ubiquitous molecule present on the surfaces of most cells, as an 
attachment factor. Attachment to cellular heparan sulfate helps in concentration of virus 
particles on the cell surface and thus enhancing their chances of cell entry, thereby 
increasing their transduction efficiency of this viral vector. The same affinity towards 
heparan sulfate, however, poses a challenge in terms of release of this pseudotyped virus 
from the producer cells. General principles concerning viral adaptation to the use of 
attachment factors and improving pseudotyped virus titers through modifying cell 
membrane components can be derived from these results. We also show that alphavirus-
glycoprotein retroviral pseudotypes require cholesterol for entry into the cells. 
Furthermore, excess cholesterol in cells facilitates the entry of alphavirus-glycoprotein 
retroviral pseudotypes. We show that alphavirus-glycoprotein pseudotypes transduce the 
acid sphingomyelinase deficient (ASMase-/-) cells derived from Niemann Pick’s disease-
model mice more efficiently than the cells from healthy mice (ASMase+/+). Thus 
alphavirus-glycoprotein pseudotypes hold a potential as suitable vectors for gene therapy/ 




CHAPTER 1. GENE THERAPY/ TRANSFER VECTORS AND RETROVIRUSES 
 
 
1.1 Introduction to Gene Therapy 
The genome of an organism has the complete set of biochemical instructions 
required for sustenance of life. If this genome carries any abnormality or mutation, it 
leads to genetic disorders. Currently available therapeutic options mostly focus on 
treating the symptoms but not curing them. Gene therapy promises to be a curative form 
of medicine.  
In gene therapy, cells carrying a defective gene are targeted and replaced with a 
healthy copy of that gene. The gene delivery can be achieved by administering genetic 
material into the body. This type of gene therapy is referred to as in vivo gene therapy 
(Figure 1.1). Gene delivery can also take place outside the body, where affected cells are 
removed from the body, delivered with genetic material followed by re-administering the 






Figure 1.1 Types of Gene Therapies 
In ex vivo gene therapy, defective cells are removed from the body and cultured. The 
genetic material is introduced into the cells outside the body, before re-injecting the cells 
back into the body. In in vivo gene therapy the corrective gene is directly administered 
into the body.  
 
Genetic material can be delivered either to the somatic (non-reproductive) cells or 
to the germline cells. The effect of delivery of genetic material to the somatic cells 
doesn’t pass on to the next generation, whereas the effect of gene delivery in germline 
cells is carried on to the next generation. Thus, the therapeutic effect of germline gene 
therapy, unlike somatic gene therapy, is permanent. However one potential hazard of the 
former method is that the negative effects can also be permanently passed down to 
subsequent generations (www.genetherapynet.com/viral-vectors.html n.d.).  
Gene therapy to cure human diseases has been proposed since a long time. In 
spite of advancement in this field, currently there is no approved treatment available. The 
first attempt at gene therapy to treat diseases in humans was done in 1990. A 4 year old 
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girl suffering from Severe Combined Immuno-deficiency syndrome (SCID), a 
monogenetic disease, which is caused due to the deficiency of adenosine deaminase 
(ADA), was treated at NIH Clinical Center through an ex vivo gene therapy approach. 
Her white blood cells were removed from her body and a healthy gene expressing ADA 
was introduced into them. These cells were re-administered into her body (Blaese R 
1995).  
Multiple gene therapy/transfer studies were performed until late nineties. In 1999, 
this field suffered a major set-back when a patient named Jesse Gelsinger, who had 
participated in a clinical trial, died within a week of receiving the treatment. He had 
deficiency of ornithine transcarbamylase (OTC), one of the enzymes required for 
converting excess nitrogen in blood into urea. The gene expressing OTC was 
administered using adenovirus vector. His body invoked a major immune reaction in 
response to the high dosage of the virus (P. N.-H. Wirth T 2013). The failure of this trial 
resulted in withdrawal of many studies. 
Despite this, there have been many studies that have shown encouraging results 
such as SERCA gene therapy for cardiac failure (Periasamy M 2008), gene therapy for 
X-linked Severe Combined immunodeficiency syndrome (Hacein-Bey-Abina S 2010), 
etc. China was the first country to approve a gene therapy product for therapeutic use (P. 
N.-H. Wirth T 2013). However, this approval wasn’t backed up by clinical trial data. 
Cerepro, an adenoviral vector carrying thymidine kinase gene, is the first gene therapy 
product used for treating malignant brain tumors to have passed phase III clinical trial (S. 
H.-H. Wirth T 2009). Glybera, an adeno-associated viral vector delivering lipoprotein 
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lipase gene, is the first gene therapy product to be recommend by European Medicines 
Agency for approval in Europe (P. N.-H. Wirth T 2013). Given the recent advancements 
in this field, gene therapy definitely seems to be an attainable therapeutic option in the 
near future. 
1.2 Gene delivery vectors 
The vehicles used for delivering the genes are known as vectors. The gene 
therapy/transfer vectors are broadly classified into viral and non-viral vectors. Liposomes 
and naked DNA delivery have been used for non-viral gene delivery. Even though these 
physical methods tend to be safer and less immunogenic than viral vectors, viral vectors 
have proven to be efficient gene delivery vectors as compared to the non-viral ones (Li 
SD 2006).  
There are many viruses that can be used as gene delivery vectors. Table 1.1 
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Retroviruses are a large group of viruses responsible for causing 
immunodeficiency syndromes and leukemias in vertebrates. These viruses contain a 
single-stranded positive-sense RNA genome, which through the process of reverse 
transcription forms a DNA intermediate. This DNA intermediate can integrate with the 
host genome leading to formation of a provirus. Retroviruses are transmitted by coming 
in close contact with infected animal, exposure to body fluids of infected animals, 
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maternofetal transmission, accidental inoculation and experimental infection (Coffin JM 
1997). Retroviruses are increasingly being used as research tools in cell and molecular 
biology. 
Retroviruses like Human immunodeficiency virus (HIV), Moloney murine 
leukemia virus (MoMuLV) etc. are used as vectors of gene therapy because they allow 
fast and stable transfer of genetic material to cells, and have strong promoter system that 
results in efficient and long lasting expression of genetic material.  However, the host 
range and tissue tropism of this viral vector are limited. 
1.4 Moloney Murine Leukemia Virus (MoMuLV) 
 MoMuLV (gammaretrovirus genus) is one of the simplest retroviruses and hence is used 
as a model for studying retroviruses. The MoMuLV is a polymorphic virion around 100-
120 A˚ in size (Figure 1.2) (Yeager M 1998). Two strands of single-stranded RNA 
genome are incorporated into the virus particle. The viral genome has a coding region 
and a non-coding region (Figure 1.3). Coding region has genes gag-pol-env that code for 
the three polyproteins, Gag (Figure 1.4), Pol and Env respectively. These are involved in 
assembly of the virion. The capsid of the virion is formed from Gag while the envelope is 
developed from the Env polyprotein and the lipid bilayer of the host. The three enzymes-
reverse transcriptase (RA), integrase (IN) and aspartic protease (PR) are derived from the 




Figure 1.2 MoMuLV particle 
The outermost layer is formed from Env glycoproteins and host-derived lipid bilayer. The 
Env glycoprotein is made up of the surface unit (SU), which contais the receptor binding 
domain and transmembrane (TM) unit, which has the fusion peptide. The lipid bilayer 
and the embedded glycoproteins constitute the envelope of the virus particle. Inside, lies 
the core made up of the Gag polyprotein. Within the core there are two strands of single-
stranded RNA genome. Along with that, there is Pol, the polyprotein which comprises of 
three enzymes: (i) reverse transcriptase, which converts the viral RNA genome into a 
DNA copy, (ii) viral aspartic protease, which leads to maturation of the virion by 
cleaving the polyproteins into their respective domains and (iii) integrase, which 
processes the DNA copy of viral genome and inserts it into the host genome to form the 
provirus. (Figures from Rein A, Advances in Virology, 2011 and Silverman RH et al., 
Nature Reviews urology, 2010) (Rein 2011) (Silverman RH 2010) 
 
 
Figure 1.3 MoMuLV genome 
The coding region of the viral genome includes the gag, pol and env regions that encode 
Gag, Pol and Env polyproteins respectively. The non-coding region has a LTR sequence, 
which has all the promoters and enhancers, the psi (Ψ) packaging sequence, a primer 
binding site (PBS) and the polypurine tract (PPT), which acts a primer for synthesis of 





Figure 1.4 Gag polyprotein 
Gag polyprotein is made up of a matrix (MA) domain, which lies on the outer side of the 
core and associates with the lipid bilayer through myristylation, a small proline rich p12 
region, which is thought to promote the release of virus particles, a capsid (CA) domain 
and a nucleocapsid (NC) domain which lies on the inner side and is in association with 
the RNA genome (Rein 2011, Shinnick TM 1981)   
 
1.5 Replication cycle of MoMuLV 
 MoMuLV infects the cell by receptor-mediated membrane fusion (Figure 1.5). The SU 
subunit of the envelope glycoprotein of the virus binds to the cell surface receptor. This 
causes structural change in the SU subunit which leads to disruption of the disulfide bond 
between the SU and TM subunits (Freed EO 1987, Pinter A 1997), exposing the fusion 
peptide of the TM subunit. Fusion between the viral and cell membranes releases the 
capsid into the cytoplasm which later disintegrates and the viral RNA escapes into the 
cytoplasm. The RNA genome is copied into DNA by reverse transcriptase. This DNA 
enters the nucleus and gets inserted into the host genome with the help of viral integrase 
to form a provirus. The integrated DNA is transcribed into mRNA which then travels out 
of the nucleus. In the cytoplasm it is translated into the assembly proteins. Envelope 
glycoproteins are synthesized from spliced mRNA and translocated to ER. Glycosylation 
takes place in the Golgi along with the furin cleavage of Env polyprotein into the SU and 
TM subunits. The SU-TM heterodimer is linked with a disulfide bond. Three 
heterodimers come together to form trimers and these are then transported to the 
membrane. Gag-Pol polyproteins, which are synthesized together as fusion protein co-
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assemble at the membrane. Myristylation of the N terminal of Gag targets it to the plasma 
membrane (Rein A 1986). An alternative glyco-Gag is also synthesized and is thought to 
target the virus assembly towards lipid rafts (Nitta T 2011). The psi packaging sequence 
helps the viral RNA to compete against the cellular RNA to be incorporated in the 
budding virus. The late motif (p12) of Gag interacts with the ESCRT machinery, which is 
involved in the budding process of the assembled virus (Rein 2011, Pornillos O 2002). 
One of the cleavage products of the Pol polyprotein, the viral aspartic protease (PR), 
plays a role in maturation of the virus particle as it cleaves the Gag molecule into its 







Figure 1.5 Replication cycle of MoMuLV 
Retrovirus entry is initiated when the virus particle binds to the cell surface receptor. 
Fusion between the viral and cell membrane releases the capsid into the cytoplasm. The 
viral RNA escapes into the cytoplasm upon disintegration of the capsid. RNA is copied 
by into DNA by reverse transcriptase. This DNA enters the nucleus and gets inserted in 
the host genome with help of viral integrase to form a provirus. The integrated DNA is 
transcribed into mRNA. mRNA is gets transported to the cytoplasm, where it is translated 
into the assembly proteins. Envelope proteins are synthesized from spliced mRNA and 
translocated to ER. Gag-Pol polyprotein which are synthesized together as fusion proteins 
co-assemble at the membrane. The psi sequence helps in packaging of the viral RNA into 
compete the budding virus. Viral aspartic protease cleaves the Gag molecule into its 
respective subunits. This step of maturation of the virus is crucial for its infectivity. 
 
1.6 Limitations of retroviruses as gene therapy vectors 
The retroviruses have three major limitations as gene therapy/transfer vectors. 
Firstly, the host range and tissue tropism are not very extensive. This limits the types of 
cells they can enter into. Secondly, there is a chance of recombination and formation of 
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replicating and competitive virus particles capable of causing active infection in 
individuals receiving the treatment (Anson 2004). And finally, clinical trials in the past 
have shown instances of insertional mutagenesis leading to oncogenesis (Anson 2004).  
Pseudotyping of the virus can be used to overcome the first two limitations. It is a 
process in which the envelope protein of the virus is replaced with an envelope protein of 
other virus. Previously, we have pseudotyped retroviruses by replacing its envelope with 
the envelope of alphaviruses in our lab. The details about alphaviruses and process of 








Alphaviruses are arthropod-borne viruses that cause severe infections in a wide 
range of vertebrates. The clinical manifestations in infected humans include fever, rash, 
arthralgia, myalgia, headaches and polyarthritis (Strauss J H 1994). Alphaviruses belong 
to the Togaviridae Family and are classified into two categories: (i) Old World viruses 
which include Semliki forest virus (SFV), Sindbis virus (SINV) and Ross River virus 
(RRV) (ii) New World viruses which include Venezuelan equine encephalitis virus 
(VEEV), Eastern equine encephalitis virus (EEEV).  
2.2 Structure of alphaviruses 
 An alphavirus is an enveloped, single-stranded, positive-sense, RNA virus 
(11.5kb) (Figure 2.1) (Strauss J H 1994). The RNA genome (Figure 2.2) is surrounded by 
the capsid, which is made up of 240 units of capsid protein. This is in turn is surrounded 
by an envelope, which is a lipid bilayer membrane with 80 spikes of envelope 
glycoprotein embedded into it (Figure 2.3). E1, E2 and E3 are the three envelope 
glycoproteins. Each spike is a trimer of an E1/E2 heterodimer (Cheng RH 1995). 
Whereas E2 is required for binding to cell-surface receptors, E1 is required for fusion of 
the viral and cellular membrane. The envelope and the inner nucleocapsid core have 
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icosahedral symmetry with triangulation number T=4 (Strauss J H 1994, Cheng RH 
1995). The E2/E1 heterodimer has an one-one association with each nucleocapsid 












Alphaviruses have 80 spikes of envelope glycoproteins (blue) embedded in the lipid 
bilayer (green), which forms its envelope. Inside this, lies the nucleocapsid core (yellow 
and red) made up of 240 units of Capsid proteins and a single strand of a positive-sense 




Figure 2.2 Alphaviral genome 
  
An alphavirus has a single-stranded, positive-sense RNA genome. The nonstructural 
proteins are translated from the genomic RNA and are involved in replication of the 
genome, whereas the structural proteins are translated from the subgenomic RNA, with a 





Figure 2.3 Alphaviral Structural Proteins 
Alphaviral structural proteins are expressed as polyproteins. The Capsid protein © 
cleaves itself after getting translated (Arrow 1). The N terminus of the remaining portion 
of polyprotein (envelope glycoproteins) has a signal sequence due to which it translocates 
into the endoplasmic reticulum, while another signal sequence anchors it in the 
membrane. A proteolytic cleavage after this signal peptide releases E3-E2 (pE2) (Arrow 
3) (Garoff H 1990).  Another proteolytic cleavage at C terminal of heavily palmitoylated 
6kD segment (Arrow 4), releases E1 which is then anchored by stop-transfer signal. 
Cleavage between E3 and E2 takes place in trans-golgi and is mediated by furin-like 
protease (Arrow 2) 
 
 2.3 Replication cycle of Alphaviruses 
The virus enters the cell via receptor-mediated endocytosis (Figure 2.4) (DeTulleo L 
1998). The presence of a cholesterol and sphingolipid rich bilayer has been shown to be 
required for entry of SINV and SFV (H. A. Kielian MC 1984, Phalen T 1991, Lu YE 
1999). Once inside the endosome, the acidic pH leads to dissociation of the E1-E2 
heterodimer complex exposing the hidden fusion loop of the E1 glycoprotein. Insertion of 
the fusion loop into the endosomal membrane is followed by formation of E1-homotrimer 
complex (H. A. Kielian MC 1985, Boggs WM 1989, Justman J 1993, Li L 2010). This 
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fusion process releases nucleocapsid core into the cytoplasm. Disassembly of the capsid 
releases he RNA genome, which is translated from two ORFs to form (I) the non-
structural polyprotein (P1234), which is required for the replication of the genome (early 
phase) and (II) the structural polyprotein (late phase). The positive strand is first 
converted to a negative strand of RNA, which is predominant during early phase. This 
negative strand, during the late phase of replication cycle is either replicated into full-
length positive genomes, which are incorporated into new virion or it is spliced into 
subgenomic positive-sense RNA. The subgenomic RNA is translated into structural 
polyprotein (C-pE2-6K-E1) (Jose J 2009) (Leung JY 2011). Upon cleavage, Capsid 
protein starts oligomerizing and then associates with the single-stranded RNA genome to 
form the nucleocapsid (Tellinghuisen TL 1999). The cleavage of Capsid protein is 
followed by the processing of the remaining polypeptide, which now consists of envelope 
glycoproteins. The N-terminus of this polypeptide has signal sequence which helps in 
translocation of the polypetide into the ER. A 30 residue-long signal sequence anchors C-
terminus of the polypeptide. A proteolytic cleavage after this signal peptide releases E3-
E2 (pE2) (Garoff H 1990).  Another proteolytic cleavage takes place in remaining the 
polypeptide between the hydrophobic 6K and E1 protein (Liljeström P 1991). The E1 and 
pE2 undergo complex folding with the help of chaperones. Disulfide bond formation 
takes place to form the pE2-E1 heterodimer in the ER (Anthony RP 1992). Post-
translational modifications like glycosylation, palmitoylation in case of E2 follow this 
(Sefton 1977). Once the heterodimer reaches trans-golgi, furin-like protease cleaves E3 
from E2 (Gaedigk-Nitschko K 1990). This cleavage is essential for entry of virus 
(Salminen A 1992 ). The glycoproteins are transported to the plasma membrane where 
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the virions are assembled. Interaction between nucleocapsid unit and E2 takes place and 













Figure 2.4 Replication cycle of alphaviruses 
Alphaviruses enter the cell via receptor mediated endocytosis. The process of fusion is 
triggered by the acidic pH in the endosomes. The RNA gnome is released in the 
cytoplasm and translated into non-structural polyproteins, which are required for 
replication of the genomic RNA, and structural polyproteins. The capsid proteins, which 
are derived from the structural polyproteins and the genomic RNA form nucleocapsid 
cores, which are transported to the plasma membrane. Envelope glycoproteins, which are 
derived from the structural polyprotein, reach the plasma membrane through secretory 
pathway. The assembly of the virus particle takes place at the plasma membrane, which is 
followed by budding. Figure adapted from Schwartz et al., Nature Reviews 




Viruses are commonly used as vectors to deliver a desired gene to target cells for 
the purpose of gene therapy or gene transfer. For gene therapy/transfer, one either needs 
to expand the host range of the gene delivery vector or narrow it down to a specific 
target. The recognition and infection of host cells by viruses depends on their envelope 
proteins. Hence by incorporating the envelope proteins of other viruses, the ability to 
enter cells other than those a virus normally infects can be conveyed to this parent virus. 
The chimeric virus having the desired host range/tissue tropism thus formed is called a 
pseudotyped virus (Sanders 2002). 
Pseudotyped viruses have many experimental and clinical applications. Gene 
therapy/transfer is one of the important applications of these pseudotyped viruses. Based 
on the therapeutic need, the range of cells targeted by the viral vector for gene 
therapy/transfer can be modified by pseudotyping the virus with the envelope of another 
virus (Sanders 2002). Apart from their utility as gene-delivery vectors, pseudotyped 
viruses can also be used as tools to study the entry of enveloped viruses. 
  Retroviruses, such as human immunodeficiency virus (HIV), feline 
immunodeficiency virus (FIV), and Moloney murine leukemia virus (MoMuLV) are used 
as gene-delivery vectors, because they allow fast and stable transfer of genes under the 
influence of strong promoters to cells (Naldini L 1996, Kafri T 1997, Poeschla EM 1998, 
Noh MJ 2010). However, they have limited host range and tissue tropism. For the 
treatment of systemic genetic disorders a viral vector needs to be pseudotyped with an 
envelope of a virus that has a broad tissue tropism. Since RRV, an alphavirus, has wide 
host range and tissue tropism, it was incorporated in ØNX pseudotyped system to 
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produce RRV-MoMuLV pseudotyped virus (Sharkey CM 2001). Recombinant 
retroviruses and lentiviruses bearing alphavirus glycoproteins have been shown to be 
efficient gene transfer/therapy vectors (Sharkey CM 2001, Kang Y 2002). Previous 
studies showed that pseudotyping with RRV was far less cytotoxic but equally efficient 
as pseudotypes incorporating envelope glycoproteins of Vesicular Stomatitis virus (VSV-
G), a prototype pseudotyped virus (Kang Y 2002). Retroviruses pseudotyped with RRV 
envelope glycoproteins were successfully used for in vivo gene-transfer studies in 
hepatocytes, glial cells, muscle tissue and airway epithelial tissue (Kang Y 2002). 
2.5 Generation of pseudotyped viruses 
 Producer ØNXnlslacZ cells (a second generation 293-T based retroviral packaging cell 
line that is stably transfected with a MoMuLV gag-pol plasmid and the MFG.S-nlslacZ 
plasmid, which produces envelope-protein-deficient, replication-incompetent MoMuLV 
particles and encodes nuclear-localized β-galactosidase) are transfected with plasmid 
encoding for alphaviral glycoproteins to generate alphaviral-MoMuLV pseudotypes 
(Figure 2.5) (Sharkey CM 2001). The gag-pol plasmid expresses the core proteins of 
MoMuLV under the influence of RSV promoter. The MFG.S-nlslacZ plasmid has the 
gene of choice, which for experimental purposes is lacZ, along with the nuclear 
localizing sequence (nls), LTR and psi (Ψ) sequence. The Ψ sequence helps in packaging 
of LacZ into the budding pseudotyped virus. These naked nucleocapsid cores however, 
are incapable of transducing the cells and require an envelope to do so. Hence these 
producer ØNXnlslacZ cells are transfected with plasmid encoding the envelope protein 
of other viruses, such as alphaviruses. The plasmid encoding for alphaviral glycoproteins 
20 
 
is expressed under the influence of CMV promoter. The retroviral promoter in the LTR 
region is required for in expression of LacZ gene into β-galactosidase. β-galactosidase 
then gets translocated to the nucleus under the effect of nuclear localizing sequence.  
The pseudotyped viruses generated using this method are non-infectious and 
replication incompetent. By replacing the MFG.S-nlslacZ gene with a vector-expressing 
gene they can be used as efficient gene-delivery agents. Since the three plasmids involved 
in formation of these pseudotypes have three different promoters, the chances of 
recombination are very minimal. This makes the retroviral pseudotypes incorporating 






Figure 2.5 Pseudotyping 
 
  
Alphaviral-MoMuLV pseudotypes are generated by transfecting producer ØNXnlslacZ 
cells with a plasmid encoding alphaviral glycoproteins (figure shows RRV-envelope 
plasmid). The ØNXnlslacZ cell-line is a second generation 293-T based retroviral 
packaging cell line that is stably transfected with the MoMuLV gag-pol and MFG.S-
nlslacZ plasmids. The pseudotyped viruses generated using this method are replication 
incompetent and function as gene-delivery agents. 
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CHAPTER 3. MATERIALS AND METHODS 
 
 
3.1 Cell lines and cell culture 
 Producer ØNXnlslacZ cells (a second generation 293-T based retroviral packaging cell 
line that is stably transfected with MoMuLV gag-pol plasmid and MFG.S-nlslacZ 
plasmid, which produces envelope-protein-deficient, replication-incompetent MoMuLV 
particles that encode nuclear-localized β-galactosidase) (Sharkey CM 2001); BHK; 
CHO22; CHO18.4 (a mutant cell line derived from CHO22 not expressing HS) (Heil ML 
2001, Jan J 1999) [generously donated by Dr. Richard Kuhn’s laboratory] were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% heat-inactivated fetal bovine 
serum (FBS) and penicillin (10 U/mL ) at 37°C in 5% CO2. NIH 3T3 cells were grown in 
DMEM with 10% calf serum (CS) and penicillin (10 U/mL) at 37°C in 5% CO2. Sf9 
insect cells were grown in Sf9/III medium with 3% FBS at 28 °C without CO2. C6/36 
mosquito cells were grown in DMEM with 10% heat-inactivated-FBS at 28 °C in 5% 
CO2, as well as in DMEM with de-lipidated heat-inactivated-FBS at 28 °C in 5% CO2. 
De-lipidated serum was obtained by centrifugation of serum in presence of Cab-O-SiL 
(Cabot Co.). Cab-O-SiL acts by adsorbing lipids in the serum. ASMase-/- mutant mouse 
skin fibroblast cells and ASMase+/+ wild-type mouse skin fibroblast cells (kindly) 
23 
 
donated by Dr. Glyn Dawson’s Laboratory) (Qin J 2012), were grown in DMEM with 
10% heat-inactivated-FBS at 37 °C in 5% CO2.  
3.2 Plasmids 
 Regions of the RRV cDNA containing amino acid substitutions T216R, T216V, N218R 
or N218V (Heil ML 2001) [kind gifts from Dr. Richard Kuhn’s laboratory] were 
removed through restriction endonuclease cutting with ScaI and RsrII. These enzymes cut 
the genomic RRV clone at nucleotides 9201 and 9568 respectively. Each of these 
fragments was individually ligated with ScaI/BglII fragment spanning nucleotides 12-
1766 and the large RsrII/BglII fragment (resulting from a partial RsrII digest) from 
nucleotide 2133 to nucleotide 12. These plasmids are designated pRRV-E2E1A-T216R, 
pRRV-E1E2A-T216V, pRRV-E2E1A-N218R and pRRV-E2E1A-N218V respectively 
according to the single amino acid change in each glycoprotein coding sequence. The 
integrity of each cloned plasmid was confirmed by sequence analysis.  
Plasmids expressing envelope glycoproteins of alphaviruses namely pRRV-
E1E2A (Sharkey CM 2001), pVEEV-E1E2, pSINV-E1E2 and pSFV-RRV-E1E2 were 
constructed by digesting the cDNA of viruses (RRVand SFV- BamHI and XbaI, VEEV-
HindIII and XbaI, SINV-BamHI and XhoI) and ligating the fragment containing E3-E2-
6K-E1 coding region into pcDNA3.1/zeo (+) cut with same enzymes. VSV-G envelope 
plasmid, pCMV-G, (Kang Y 2002) and penv1min (Taylor GM 1999) were used for 
expression of Vesicular Stomatitis virus envelope glycoproteins and MoMuLV envelope 
glycoproteins respectively. pBACgus1-RRV-E1E2 was constructed by digesting pRRV-
E1E2A with BglII and AvrII and inserting the fragment containing the E3-E2-6K-E1 
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coding region into pBACgus1 plasmid cut with the same enzymes. Bacmid bMW033, 
which expresses replication-competent baculovirus with intact envelope glycoprotein, 
gp64, and bacmid expressing baculovirus cores deficient in gp64, bMW024, were kindly 
gifted by Dr. Colin T. Dolphin’s laboratory (Westenberg M 2013). 
3.3 Production of virus by transient expression of envelope glycoproteins 
 4,000,000 producer ØNXnlslacZ cells were grown overnight on 10 cm plates. The 
following day they were washed with phosphate-buffered-saline solution (PBS), and 10 
mL of fresh growth medium was added to them. Plasmids expressing RRV envelope 
glycoproteins: pRRV-E1E2A, pRRV-E1E2A-T216R, pRRV-E1E2A-N218R, pRRV-
E1E2A-T216V and pRRV-E1E2A-N218V were incubated with 12 µL PLUS reagent 
(Life Technologies) in DMEM for 15 minutes followed by incubation with 18 µL 
Lipofectamine (Life Technologies) for 15 minutes in DMEM at room temperature. Each 
of these plasmids was then added to the respective plates containing the producer cells 
grown overnight, and the plates were incubated at 37 °C in 5% CO2. 3 hours after 
incubation the liquid from each plate was replaced with 10 mL of fresh growth medium. 
This was further incubated for 48 hours at 37 °C in 5% CO2 after which the supernatant 
medium containing RRV-MoMuLV pseudotyped virus was collected from each of these 
plates. 
 4,000,000 producer ØNXnlslacZ cells were grown overnight in 10 cm plates. The 
following day, they were washed with phoshate buffered saline solution (PBS) and 10 
mL fresh medium was added to them. Envelope glycoproteins expressing plasmids 
pRRV-E1E2A, pVEEV-E1E2, pSINV-E1E2 and pSFV-E1E2 were incubated with 18 µL 
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of Lipofectamine 2000 (Life Technologies) for 15 minutes in DMEM at room 
temperature. Each transfection mix containing the envelope plasmids was then added to 
the respective plates containing the producer ØNXnlslacZ cells grown overnight, and 
then the plates were incubated at 37 °C in 5% CO2. 4 hours after incubation the medium 
from each plate was replaced with 10 mL fresh medium and this was further incubated 
for 48 hours at 37 °C in 5% CO2. The supernatant media overlying these cells contained 
pseudotyped virus. MoMuLV pseudotyped with MoMuLV glycoproteins and MoMuLV 
pseudotyped with VSV-G were produced similarly.  
3.4 Transduction assay 
10 mL of supernatant media overlying producer ØNXnlslacZ cells were collected 48 
hours after transfection and passed through a 0.45 µm filter. Hexadimethrine bromide (5 
µg/mL) was added to the filtered supernatant media. This media was used to transduce 
target cell-lines, NIH 3T3, BHKs, CHO22 and CHO18.4 (a mutant cell line derived from 
the parental CHO22 that does not express HS). After 4 hours of incubation, the media 
were replaced with fresh media. 48 hours after transduction, cells were stained with X-gal 
(Taylor GM 1999).Transduction units were then calculated by the formula: Transduction 
Units/ml (TU/mL) = (No. of blue cells/Total number of cells)*(No. of cells 
plated/Volume of media added). 
3.5 Immunoblot assay 
10 mL of supernatant media from producer cells transfected with different plasmids were 
passed through a 0.45 µm filter. The virus particles were collected by ultra-centrifugation 
of the supernatant media through a 30% sucrose cushion in Beckman 50.2 Titanium rotor 
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at 28000 rpm. The pellets of virus particles accumulated at the bottom were suspended in 
SDS-PAGE buffer containing 2% β-mercaptoethanol. The viral pellets were analyzed by 
SDS-PAGE gel and then transferred to nitrocellulose paper. Presence of the envelope 
glycoproteins RRV-E2 and RRV-E1 along with the   MoMuLV-Capsid (p30) proteins 
was detected by incubating with rabbit anti-E2 (1:5000), rabbit anti-E1 (1:5000) and goat 
anti-Raucher Leukemia virus-Capsid (p30) polyclonal primary antibodies (1:1000) 
respectively. Anti-rabbit antibodies (Chemicon) and anti-goat antibodies coupled with 
horseradish peroxidase were used as secondary antibodies (1:5000) to detect RRV 
envelope glycoproteins and MoMuLV capsid proteins respectively. The amount of 
protein present was measured based on chemiluminescence using FluorChem E imaging 
system. The lysate and cell-debris samples were obtained by lysing the producer 
ØNXnlslacZ cells transfected with different RRV envelope plasmids, using lysis buffer 
containing 1% Triton-X 100, 50 mM Tris, 5 mM EDTA and 150 mM NaCl. Immunoblot 
analysis of these preparations was also done as above. 
3.6 Immunofluorescence assay 
48 hours after transfection of CHO22 and CHO18.4 cell lines with RRV-envelope 
encoding plasmids, cells were washed with PBS, fixed with 2% formaldehyde and 
permeabilized with 0.1% Triton-X 100. This was followed by blocking them with 1% 
BSA solution after which they were incubated overnight at 4°C with (1:100) primary 
Anti-E2 (rabbit) antibodies. After washing off the excess primary antibodies, cells were 
incubated with (1:500) Alexa Fluor 488-coupled anti-rabbit antibodies for 1-2 hours at 
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room temperature followed by removal of excess antibodies by washing. The cells were 
visualized by fluorescence microscopy (Olympus IX) using MetaMorph software.  
3.7 Addition of Heparinase I to Producer cells 
44 hours after transfecting producer ØNXnlslacZ cells with RRV envelope plasmids, the 
supernatant media overlying the cells were replaced with fresh media, and the cells were 
incubated with 6 µg/mL Heparinase I at 37°C. After 4 hours the supernatant media were 
collected and passed through a 0.45 µm filter.  Hexadimethrine bromide (5 µg/mL) was 
added to the filtered supernatant media. These media were used to transduce target cell 
lines (NIH 3T3, BHKs, CHO22 and CHO18.4) 
3.8 Addition of Heparinase I to target cells 
 Target cells (BHK, CHO22 and CHO18.4) grown overnight were incubated with 
increasing concentrations (0, 2, 4, 6 µg/mL) of Heparinase I, an enzyme that cleaves HS 
from the cell surface, for one hour at 37°C. After being washed with PBS, these cells 
were transduced using supernatant media from producer ØNXnlslacZ cells as explained 
earlier.  
3.9 Normalization following quantitative analysis of the immunoblot assay 
 10 mL supernatant media from producer cells transfected with different plasmids were 
collected and replaced with 10 mL fresh media. Collected media were passed through a 
0.45 µm filter and subjected to ultracentrifugation in a Beckman 50.2 Titanium rotor at 
28000 rpm with a 30% sucrose cushion to obtain pellets of viral particles. An 
immunoblot assay of virus pellets using anti-E2 antibodies was performed. Using Image J 
software, the amount of RRV-E2 glycoprotein in each virus pellet was quantified. Based 
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on these values the media overlying the producer cells was normalized across all the 
samples and used for transduction of target cells (NIH 3T3, BHK, CHO22 and 
CHO18.4). Normalization was performed by appropriate dilutions of the media 
containing WT-RRV, T216R-RRV, T216V-RRV, N218R-RRV and N218V-RRV 
pseudotyped viruses. 
3.10 Transduction assays in cells treated with lipid-lowering drugs 
The target cells (BHK and NIH-3T3) were incubated with 4 µg/mL of lovastatin (Sigma-
Aldrich) for 12 hours followed by another 12 hours of incubation with 2.5 mM of methyl-
beta-cyclodextrin (ß-mCD) (Sigma-Aldrich) 4 µg/mL of lovastatin, after which they were 
washed with phosphate-buffered-saline solution (PBS). Supernatant media overlying the 
producer ØNXnlslacZ cells were replaced with serum-free media, and the cells were 
incubated for 5 hours. These serum-free media containing the pseudotyped viruses were 
collected after passing them through a 0.45 µm filter. Hexadimethrine bromide (5 µg/mL) 
was added to filtered supernatant media. These media were added to the target cells, 
NIH-3T3 and BHK for transduction. After 24 hours of incubation, the media were 
replaced with fresh media. 48 hours after transduction, cells were stained with X-gal. 
Transduction units were then calculated by the formula (TU/mL) = (No. of blue cells/ 
Total number of cells)*No. of cells plated/ Volume of media added. These experiments 
were also performed by replenishing the cholesterol content of cholesterol-depleted cells. 
Repletion of cholesterol was done by incubating cholesterol-depleted cells in media 
containing 50 µg/mL of cholesterol for 1 hour. 
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3.11 Production of baculovirus virus pseudotyped with alphavirus envelope 
glycoproteins 
 500,000 Sf9 cells were grown for an hour on 6 cm plates. Following that the media were 
replaced with 6 mL of fresh Sf9/III + 3% FBS media. Plasmid pBACgus1-RRV-E1E2 
was coincubated with bMW024 and 18 µL of Cellfectin (Life technologies) for 30 
minutes in 500 µL Sf9/III medium at room temperature. The transfection mix was added 
to the plate containing Sf9 cells. 24 hours after incubation the medium from the plate was 
replaced with 6mL fresh medium and this was further incubated for 4 days at 28 °C. The 
supernatant medium containing baculovirus pseudotypes was passed through a 0.45 µm 
filter and used for the transduction assay. Baculovirus incorporating VSV-G was 
produced by co-transfection of pBACgus1-VSV-G and bMW024. Replication-competent 
baculovirus was produced by transfection of cells with bMW033. 
3.12 Transduction assay in C6/36 cells grown in sterol-free conditions 
5 µg/mL of hexadimethrine bromide was added to filtered supernatant media containing 
the baculovirus pseudotypes. These media were added to the C6/36 cells grown in 6 well 
plates.  After 12 hours of incubation, the media were replaced with fresh media. 72 hours 
after transduction, cells were visualized under a fluorescent microscope (Olympus IX) 
using MetaMorph software. Transduction units were calculated using the formula stated 
above after counting the fluorescent cells. 
3.13 Transduction of ASMase-/- cells 
 MoMuLV pseudotypes with alphavirus glycoproteins were produced as mentioned 
above. The supernatent media overlying producer ØNXnlslacZ cells were used to 
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transduce target ASMase-/- and ASMase+/+ cells. The media were replaced with fresh 
media after 24 hours. 48 hours after transduction, cells were stained with X-gal and 
counted. Transduction units were then calculated. 
3.14 Verification of cholesterol concentrations in ASMase-/- cells and ASMase+/+ 
cells 
 The difference in the concentration of cholesterol in ASMase-/- and ASMase+/+ cells 
was verified by a fluorometric cholesterol assay. Cholesterol was extracted from one 
million cells by lysing them using 200 µL of chloroform: methanol solution (v/v 2:1). 
These samples were dried by allowing the solvent to evaporate at room temperature and 
resolubilized using cholesterol-assay buffer. The concentrations of cholesterol in these 
cells were determined using fluorometric cholesterol assay kit (Caymen Chemicals) and 





CHAPTER 4. ROLE OF HEPARAN SULFATE IN ENTRY AND EXIT OF ROSS 




The role of heparan sulfate (HS) in alphavirus entry is a topic of considerable ongoing 
investigation. Variants of Ross River virus (RRV) that bind to HS have previously been 
selected by serial passaging in cell culture. To explore the effects of mutations that 
convey HS utilization specifically upon the process of entry, we pseudotyped Moloney 
Murine Leukemia virus (MoMuLV), with the envelope of RRV. We substituted amino-
acid residues 216 and 218 on RRV-E2-envelope glycoprotein with basic amino-acid 
residues, because these mutations were previously shown to confer upon the virus an 
ability to bind HS. However, pseudotyped virus incorporating the basic amino-acid 
substitutions possessed lower transduction titers. Using immunoblot and 
immunofluorescence assays, we demonstrate that the affinity towards HS impeded 
release of pseudotyped virus from producer cells. Addition of heparinase to the HS-
expressing target cells reduces the transduction efficiency of the virus carrying the basic 
amino-acid substitutions, whereas no such effect is seen in cells lacking HS. These virus 
particles had enhanced transduction capacity that was dependent upon utilization of HS 
as an attachment factor. However, increased affinity towards HS also affected viral egress 
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negatively. This is reminiscent of the interaction between influenza virus and sialic acid, 
in which the former utilizes the latter as an attachment factor for its entry, but the same 
sialic acid, in the absence of neuraminidase, hinders viral release. General principles 
concerning viral adaptation to the use of attachment factors and improving pseudotyped 
virus titers through modifying cell membrane components can be derived from these 
results. 
4.2 Introduction 
Viruses are commonly used as vectors to deliver a desired gene to the target cells 
for the purpose of gene therapy or gene transfer. Retroviruses, such as human 
immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), and Moloney 
murine leukemia virus (MoMuLV) may be useful as gene-delivery vectors, because they 
allow stable transfer of genes under the influence of strong promoters to cells (Naldini L 
1996, Kafri T 1997, Poeschla EM 1998, Noh MJ 2010). Whereas the recognition and 
infection of host cells by viruses depends on their envelope proteins, incorporating the 
envelope proteins from other viruses can convey to the parent virus the ability to enter 
different cells than those it normally infects. These chimeric viruses are called 
pseudotyped viruses. Recombinant retroviruses and lentiviruses bearing alphavirus 
glycoproteins have been created and have been shown to be efficient gene 
transfer/therapy vectors (Sharkey CM 2001, Kang Y 2002). Apart from their utility as 
gene transfer/therapy vectors, alphavirus pseudotypes have been used as tools to study 
the entry of alphaviruses.  
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 Alphaviruses are arthropod-borne viruses that cause severe infections in a wide 
range of vertebrates. The clinical manifestations in infected humans include fever, rash, 
arthralgia, myalgia, headaches and polyarthritis (Strauss J H 1994). Alphaviruses are 
classified into two categories: (i) Old World viruses, including Ross River virus (RRV), 
Semliki Forest virus (SFV), Chikungunya virus  (CHKV) and Sindbis virus (SINV) and 
(ii) New World viruses, Venezuelan equine encephalitis virus (VEEV) and Eastern 
equine encephalitis virus (EEEV) (Strauss J H 1994). 
An alphavirus is an enveloped, single-stranded, positive-sense RNA virus 
(11.5kb) (Strauss J H 1994). The RNA genome is surrounded by the capsid shell, which 
is made up of 240 units of the capsid protein. This in turn is surrounded by an envelope 
consisting of the glycoproteins E1, E2, and E3 embedded in a cell-membrane-derived 
lipid bilayer. Each spike is a trimer of an E1/E2 heterodimer (Cheng RH 1995), and E3 is 
non-stoichiometrically abundant. The envelope and the inner nucleocapsid core share 
icosahedral symmetries with triangulation number T=4 (Strauss J H 1994, Cheng RH 
1995).  
RRV, like other alphaviruses, has a wide host range and tissue tropism, as their 
infectious cycle requires infecting both mammals and insects (Jose J 2009, C.-V. C. 
Kielian MC 2010, Kahl CA 2004).  Alphaviruses enter the cells via receptor-mediated 
endocytosis (DeTulleo L 1998, Sharkey CM 2001, C.-V. C. Kielian MC 2010). Binding 
to receptors and attachment factors is mediated by E2 glycoproteins, whereas E1 
glycoproteins mediate fusion of the viral and endosomal membranes (Strauss J H 1994, 
Smith TJ 1995). Many proteinaceous receptors are thought to be responsible for 
internalization of alphaviruses particles. However, these receptors have not been 
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characterized completely (C.-V. C. Kielian MC 2010, Jose J 2009). Cell-surface 
attachment factors, which facilitate the initial binding of alphaviruses and thus increase 
the concentration of virus particles on the cell surface, such as DC-SIGN and L-SIGN 
have been suggested to play a role in alphaviral entry (N. E. Klimstra WB 2003). 
Heparan sulfate (HS), an attachment factor used by a number of viruses, such as human 
papilloma virus, hepatitis C virus, most herpes viruses, adeno-associated virus, dengue 
virus, vaccinia virus, yellow fever virus and human respiratory syncytial virus (Giroglou 
T 2001, Barth H 2003, S. P. Shukla D 2001, Summerford C 1998, Chen Y 1997, Chung 
CS 1998, Germi R 2002, Feldman SA 2000), has also been proposed to be involved in 
alphaviral entry (G. D. Byrnes AP 1998, Zhu W 2010, C.-N. J. Gardner CL 2013). In 
particular, it has been proposed that capacity to use HS as an attachment factor plays a 
role in the tissue tropism of Eastern Equine Encephalitis virus (E. G. Gardner CL 2011). 
HS is ubiquitously found in the human body on the cell surfaces and in the 
extracellular matrix. It is a glycosaminoglycan made up of repeating units of uronic acid 
and glucosamine with varying degrees of sulfation (Figure 4.1), which confers a negative 










Figure 4.1 Structure of Heparan Sulfate 
HS is glycosaminoglycan made up of repeating units of uronic acid and glucosamine with 
varying degrees of sulfation. 
 
Sindbis virus has been shown to use HS as an attachment factor (G. D. Byrnes AP 
1998). It was later shown that serial passaging in cell culture led to adaptive mutations in 
Sindbis virus, which led to its selection of HS as an attachment factor (R. K. Klimstra 
WB 1998).  Similar studies done in RRV revealed that serial passaging in chick embryo 
fibroblasts led to mutations at position 218 on the E2 envelope glycoprotein that resulted 
in replacement of the original Asparagine residue with Lysine (Kerr PJ 1993). 
Incorporation of these N218R and N218K mutations in RRV was shown to permit RRV 
to utilize HS as an attachment factor (Heil ML 2001). Similarly, basic amino-acid 
substitutions of residue 216 of RRV leads to utilization of HS as attachment factor (ML 
2001). It was also shown that even though substitutions did not result in formation of the 
HS-binding motifs XBBXBX or XBXBBBX (Figure 4.2), the electrostatic interaction 
between negatively charged HS and basic amino-acids residues clustered around the 
receptor-binding region of the E2 glycoprotein (Figure 4.3 A and B) made utilization of 






Figure 4.2 RRV-E2 Envelope glycoprotein amino-acid sequence 
 
  
Amino acid residue T216 and N218 (arrows) of RRV-E2 envelope glycoprotein were 
substituted with basic amino-acid residues, namely arginine.  The amino-acid sequence of 
the RRV-E2 envelope glycoprotein (Figure 4.2A) contains other basic amino-acid 






Figure 4.3 RRV-E2 Envelope glycoprotein and HS 
 
We have previously described pseudotyping of recombinant retroviruses and 
lentiviruses with alphaviral glycoproteins, including those of RRV (Sharkey CM 2001, 
Kang Y 2002, Kahl CA 2004). In vivo gene transfer to hepatocytes and neuroglial cells 
was successfully achieved by pseudotyping lentivirus with RRV envelope glycoproteins 
Substitution of amino-acid residues T216 and N218 with basic amino-acid residues does 
not result in formation of either of the HS binding motifs, XBBXBX or XBXBBBX. 
However, these residues along with other basic amino-acid residues cluster around the 
peak of the RRV-E2 envelope glycoprotein (Figure 4.3A) (Zhang W 2005). Thus, the 
receptor-binding region of RRV-E2 glycoprotein develops electropositive charge around 
itself. This results in increased affinity of RRV-E2 glycoprotein towards negatively 
charged heparan sulfate. Cryo-electron microscopy imaging shows HS bound to N218R 






(Kang Y 2002). In order to explore additional potential advantages of alterations to the 
viral glycoproteins for transduction by RRV-MoMuLV pseudotyped virus, we created 
RRV-envelope glycoproteins with the substitutions of basic amino-acid residues that had 
been previously demonstrated to promote utilization of HS as an attachment factor for 
RRV. We demonstrate that these substitutions promote the utilization of HS by the RRV 
glycoprotein-pseudotyped retrovirus. Interestingly, these substitutions also appear to 
reduce the release of pseudotyped virus from producer cells. Incorporation of 
substitutions therefore has both advantages and disadvantages for gene transduction by 
alphavirus-pseudotyped retroviruses and lentiviruses. 
4.3 Results 
4.4.1 Transduction by T216R-RRV and N218R-RRV pseudotyped viruses is lower 
in both HS expressing as well as non-expressing cell lines 
 To determine whether substituting amino-acid residues of RRV-envelope glycoproteins 
with basic amino-acid residues made the virus utilize HS and thereby increase its 
transduction efficiency, T216R-RRV and N218R-RRV pseudotyped viruses were 
studied. Pseudotypes with no substitutions in envelope glycoproteins, WT-RRV, and 
pseudotypes with envelope glycoproteins containing substitutions of residues 216 or 218 
with Valine, T216V-RRV and N218V-RRV, were used as controls. Transduction assays 
were performed using these pseudotyped viruses. The data show that the transduction 
titers of WT-RRV, T216V-RRV, N218V-RRV pseudotyped viruses were higher than 
those of pseudotyped viruses with basic amino-acid substitutions (T216R-RRV and 
















Figure 4.4 T216R-RRV and N218R-RRV pseudotypes have lower transduction titers 
 
  
Supernatant media overlying producer ØNXnlslacZ cells producing WT-RRV, T216R-
RRV, T216V-RRV, N218R-RRV and N218V-RRV pseudotyped viruses respectively 
were collected and passed through a 0.45 µm filter.  Hexadimethrine bromide (5 µg/mL) 
was added to the filtered supernatant media. This media was used to transduce target cell-
lines (A) NIH 3T3, (B) BHKs, (C) CHO22 (parent cell-line) and (D) CHO18.4 (cell-line 
not expressing HS). The transduced target cells were stained with X-gal and transduction 
titers were calculated. The experiments were repeated thrice. The values shown by the 






















































































4.3.2 T216R-RRV and N218R-RRV envelope glycoproteins are retained in the 
producer cells 
To investigate the reason for lower transduction titers in T216R-RRV and N218R-RRV, 
immunoblot assays were carried out. Immunoblot analysis (Figure 4.5) of the pellets 
containing the viral particles that were collected after ultra-centrifugation showed that 
there was very little incorporation of the T216R-RRV and N216R-RRV-envelope 
glycoproteins as compared to that of the WT-RRV, T216V-RRV and N218V-RRV-
envelope glycoproteins. The amount of capsid protein in the viral pellets observed 
however was equal across all the samples. Thus the virus particles from T216R-RRV and 
N218R-RRV samples were lacking the envelope glycoprotein around the retroviral cores. 
This explains the reason for lower TU/mL in these samples. Further, the amounts of 
envelope glycoproteins and capsid proteins in the lysates obtained from producer 
ØNXnlslacZ cells were the same across in all samples. This shows that the mutations did 
not affect the production of the T216R-RRV and N218R-RRV envelope glycoprotein. 
The cell debris, which is the insoluble part of producer cell (parts of the cells resistant to 
1% Triton-X 100 lysis solution), however, contained higher levels of the glycoproteins in 
the T216R-RRV and N218R-RRV expressing cells as compared to wild-type, T216V-
RRV and N218V-RRV expressing cells. The quantities of the capsid proteins were same 
across all the samples. This could suggest that the envelope glycoproteins of T216R-
RRV, N218R-RRV are being retained within the producer cells. Thus even though 
envelope and capsid proteins were produced in equal quantities in all samples, greatly 
reduced quantities of complete pseudotyped virus particles were not formed in T216R-
RRVand N218R-RRV samples. Envelope glycoproteins transfected with plasmids 
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encoding envelopes with these mutations, were retained within producer ØNXnlslacZ 
cells and only naked MoMuLV cores lacking the envelope were released. 
 
Figure 4.5 T216R-RRV and N218R-RRV envelope glycoproteins are inefficiently 
incorporated in pseudotyped virus 
 
  
Virus pellets (A) were spun down from supernatant media overlying producer 
ØNXnlslacZ cells transfected with respective RRV-envelope encoding plasmids, while 
the lysate (B) and the cell debris (C) were obtained by lysing the same producer 
ØNXnlslacZ cells. These preparations were run on SDS-PAGE gels and transferred on to 
nitrocellulose paper. RRV-envelope glycoproteins (E1 and E2) and MoMuLV Capsid 
proteins in these samples were detected by immunoblotting with rabbit anti-E1, rabbit 
anti-E2 and goat anti-Capsid (p30) polyclonal primary antibodies (1:5000) respectively, 
followed by secondary antibodies coupled with horseradish peroxidase.  These 
experiments were performed thrice. 
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4.4.3 Attachment of T216R-RRV and N218R-RRV envelope glycoproteins to HS 
leads to retention of these glycoproteins within the cells producing them. 
Immunoblot assays showed that the envelope glycoproteins of T216R-RRV and N218R-
RRV were retained within the producer ØNXnlslacZ cells. To show that the retention of 
glycoproteins could be due to their affinity towards HS expressed by the producer cells, 
an immunofluorescence assay was performed. Since virus particles released from 
producer ØNXnlslacZ can reenter those same cells, the study of this exit process cannot 
be isolated from the entry process using immunofluorescence assay in these cells. Hence 
to study the role of HS in the retention of the envelope glycoproteins, the glycoprotein 
expressing plasmids were transfected in to CHO22 and CHO18.4 cell-lines. Results 
showed that there was excess retention of T216R-RRV and N218R-RRV envelope 
proteins in CHO22 cells along the secretory pathway during transport to the plasma 
membrane as compared to WT-RRV, T216V-RRV and N218V-RRV envelope 
glycoproteins (Fig. 3 A and Supplemental Fig. 1).  In CHO 18.4, a cell line that does not 
express HS, no excess retention of T216R-RRV and N218R-RRV envelope glycoproteins 
was seen in comparison to rest of the samples (Fig. 3 B). It can be concluded that the 
affinity of T216R-RRV and N218R-RRV glycoproteins towards HS leads to their 
intracellular retention in virus-producing cells, and predominantly naked MoMuLV 
cores, incapable of transducing target cells, are released from cells producing these 





Figure 4.6 Intracellular retention of T216R-RRV and N218R-RRV in HS-expressing 
cells 
  
(A) CHO22 and (B) CHO18.4 were transfected with respective RRV-envelope plasmids. 
After fixing and permeabilizing the cells, they were incubated with primary Anti-E2 
(rabbit) antibodies. After washing off the excess primary antibodies, cells were incubated 
with Alexa Fluor 488-coupled anti-rabbit antibodies and visualized under fluorescent 
microscope (rendered red color). (C) CHO22 cells expressing T216R and N218R RRV 
E2-glycoproteins (green fluorescence) were probed with Golgi-specific marker 
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4.3.4 Attachment of T216R-RRV and N218R-RRV Envelope Glycoproteins to HS 
hinders the release of virus particles 
To determine whether the affinity of RRV envelope glycoproteins towards HS expressed 
on the surface of the producer cells affects the release of virus particles Heparinase I was 
added to the producer ØNXnlslacZ cells. The aim of this experiment was to see whether 
cleaving of HS from the surface of these producer cells facilitates the release of T216R-
RRV and N218R-RRV pseudotyped viruses and thus increases their transduction 
efficiency. T216R-RRV and N218R-RRV pseudotyped viruses collected from producer 
ØNXnlslacZ cells treated with Heparinase I have higher transduction titers as compared 
to the ones not treated with Heparinase I (Figure 4.7). Addition of Heparinase I to 
producer ØNXnlslacZ cells producing WT-RRV, T216V-RRV and N218V-RRV 
pseudotyped viruses shows no effect on their respective transduction efficiency. Thus HS 
expressed on surface of producer ØNXnlslacZ cells hinders the process of release of 

















Figure 4.7 Addition of Heparinase I to Producer ØNXnlslacZ cells releases T216R-RRV 































Sample T-value P-value 
WT  1.24 0.342 
T216R -10.55   0.009 * 
T216V  0.38 0.741 
N218R -4.82   0.040* 
N218V -0.69 0.561 
Producer ØNXnlslacZ cells transfected with respective RRV-envelope plasmids are 
treated with Heparinase I. Supernatant media were collected from these cells and used for 
transduction of target cells (BHK) as described earlier. Transduction titers were 
calculated for each experiment which was repeated thrice. The graph represents 
transduction titers, where 100% TU/mL for WT, T216R, T216V, N218R and N218V are 
6090, 1650, 3860, 1760 and 4510 TU/mL respectively. The effect of addition of 
Heparinase I to producer cells is shown statistically using the paired T-Test in the table 
alongside (Table 4.1). 
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4.3.5 T216R-RRV and N218R-RRV pseudotyped viruses utilize HS as an 
attachment factor 
 To investigate whether T216R-RRV and N218R-RRV pseudotyped viruses utilize HA as 
an attachment factor, Heparinase I was added to the target cells. Heparinase I cleaves HS 
from the cell surface by breaking the α (1-4) glycosidic bond of HS. The data 
demonstrate (Figure 4.8) that in BHK and CHO22 cells, as the concentration of 
Heparinase I increases, the transduction titers of T216R-RRV and N218R-RRV 
pseudotyped viruses decrease, whereas transduction titers of WT-RRV, T216V-RRV and 
T218V-RRV pseudotyped viruses do not change drastically. However, in CHO18.4 the 
transduction titers remains equal across all samples irrespective of Heparinase I 
concentration. In addition, whereas transduction by WT-RRV, T216V-RRV and T218V-
RRV pseudotyped viruses in CHO22 and CHO18.4 cells is approximately equivalent, 
transduction by T216R-RRV and N218R-RRV pseudotyped viruses is higher in CHO22 
cells than in CHO18.4 cells.  Furthermore, treatment of the CHO22 cells with heparinase 
reduces transduction by the T216R-RRV and N218R-RRV pseudotyped viruses 
approximately to the level seen in CHO18.4 cells. Therefore in cell lines expressing HS, 
the transduction efficiency of T216R-RRV and N218R-RRV pseudotyped viruses 
decreases, as the amount of cell surface HS decreases, whereas no such effect is seen in 
cell lines not expressing HS. Thus, these data demonstrate that T216R-RRV and N218R-




Figure 4.8 Heparinase treatment of target cells reduces transduction by T216R-RRV and 
N218R-RRV pseudotyped viruses 
 
  
Target cells (A) BHK, (B) CHO22 and (C) CHO18.4 were treated with increasing 
concentrations of Heparinase I for 1 hour before transducing them with WT-RRV and 
mutant pseudotyped virus, respectively. The experiments were performed in triplicate. 
The correlation between concentrations of Heparinase I and transduction titers for each 
sample was determined by calculating Pearson coefficients using Minitab software in 




































































WT 0.008  0.976 
T216R -0.842 *0.001 
T216V 0.085  0.792 
N218R -0.896 *0.0001 





WT -0.159  0.707 
T216R -0.737 *0.037 
T216V -0.105  0.805 
N218R -0.848 *0.008 





WT 0.365 0.374 
T216R 0.132 0.755 
T216V -0.129 0.761 
N218R 0.143 0.763 
N218V 0.257 0.539 































Table 4.2 Pearson Coefficient CHO22  
 




4.3.6 Transduction efficiency of T216R-RRV and N218R-RRV is higher in cell lines 
expressing HS 
 Intracellular retention of the T216R-RRV and N218R-RRV glycoproteins results in 
markedly reduced transduction efficiencies by the pseudotyped virus recovered from the 
supernatant medium of producer cells.  It may be that there are fewer virus particles that 
bear alphavirus glycoproteins and/or that virus particles bear fewer glycoproteins. To 
investigate whether attachment to HS expressed on target cells increases the transduction 
efficiency by the virus particles bearing the low quantities of T216R-RRV and N218R-
RRV glycoproteins that are released, normalization of virus concentration by 
glycoprotein content was performed. The RRV-E2 envelope glycoprotein content of the 
virus particles collected by ultracentrifugation of the supernatant media of each of the 
pseudotyped-virus producing cells was measured by immunoblotting.  The data show 
(Figure 4.9) that after normalization based on the amount of RRV-E2 glycoprotein, the 
transduction efficiency for T216R-RRV and N218R-RRV pseudotyped viruses were 
significantly higher than that of wild type, T216V-RRV and T218V-RRV pseudotyped 
viruses in NIH 3T3, BHK and CHO22 cells. In CHO18.4, however, there was no 
significant difference in the transduction efficiency across these samples. Thus, in cell 
lines expressing HS, when the amount of RRV-E2 glycoprotein protein is equal across all 
the samples, T216R-RRV and N218R-RRV pseudotyped viruses have higher 





Figure 4.9 T216R-RRV and N218R-RRV pseudotyped viruses possess higher 





Virus was collected by ultracentrifugation from supernatant media overlying producer 
ØNXnlslacZ cells transfected with respective RRV-envelope encoding plasmids.  The 
virus-containing samples were analyzed by SDS-PAGE and transferred onto 
nitrocellulose paper. RRV-E2 glycoprotein was detected by immunoblotting with rabbit 
anti-E2 primary and anti-rabbit secondary antibodies coupled with horseradish 
peroxidase. Using Image J software, (A) the amount of RRV-E2 glycoprotein in each 
virus sample was quantified. A representative image is shown.  The amount of media 
added to target cells (B) NIH-3T3, (C) BHK, (D) CHO22 and (E) CHO18.4, for 
transduction was normalized against the amount of RRV-E2 glycoprotein present in the 
given sample.  The transduction of the CHO22 and CHO18.4 cells was performed with 
different starting samples of the five viruses, so the transduction efficiencies measured in 
this experiment between the two cell lines cannot be directly compared. The experiments 
were repeated thrice. The values shown by the graph represent the mean TU/mL values 
































































































Pseudotyped viruses have many experimental and clinical applications. Gene 
therapy/transfer is one of the important applications of these pseudotyped viruses. Based 
on the therapeutic need, the range of cells targeted by the viral vector for gene 
therapy/transfer can be either expanded or narrowed by pseudotyping the virus with the 
envelope of another virus (Sanders 2002). For the treatment of systemic genetic disorders 
a viral vector needs to be pseudotyped with an envelope of a virus that has a broad tissue 
tropism. Since RRV, an alphavirus, has wide host range and tissue tropism, it was 
incorporated in ØNX pseudotyped system to produce RRV-MoMuLV pseudotyped virus 
(Sharkey CM 2001). Previous studies showed that pseudotyping with RRV was far less 
cytotoxic but equally efficient as VSV-G (Kang Y 2002). Retrovirus pseudotyped with 
RRV envelope glycoproteins was successfully used for in vivo gene transfer in 
hepatocytes, glial cells, muscle tissue and airway epithelial tissue (Kang Y 2002). To 
further enhance the transduction efficiency and further broaden the range of cells that can 
be targeted by the pseudotyped viral vector additional modifications of these envelope 
glycoproteins are needed. 
Earlier studies in RRV show that amino acid T216 on RRV-E2 glycoprotein is the 
site involved in interaction with the receptors (Smith TJ 1995). The RRV48 strain of 
RRV normally does not utilize HS as an attachment factor. Serial passaging of this strain 
led to mutations on the E2 envelope glycoprotein in which the original amino-acid 
residues were replaced with basic amino-acid residues (Kerr PJ 1993).  Further studies 
showed that site-directed mutagenesis involving replacement of threonine residue at 216 
or the neighboring asparagine residue at 218 with a basic amino acid residue confers 
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upon the virus an affinity towards a negatively charged molecule like HS (Heil ML 
2001). Cryo-electron microscopy and image reconstruction studies of RRV-E2 
glycoprotein bound to heparin further confirmed this (Zhang W 2005).  
Substituting the amino-acid residues at 216 and 218 sites on RRV-E2 glycoprotein with 
basic amino acid residues in the RRV-MoMuLV pseudotyped virus, allows the 
pseudotyped virus to use HS, an ubiquitous molecule present on most of the cell surfaces, 
as an attachment factor.  Using HS as an attachment factor increases the concentration of 
the virus on the cell surface, which can later be internalized by cell surface receptors via 
endocytosis. Thus the three-dimensional search for the receptor is reduced to a two-
dimensional search, which increases the efficiency of cell entry, thereby enhancing the 
transduction efficiency of the pseudotyped vector. HS binding ability could also 
potentially alter the tissue tropism of this viral vector (Kang Y 2002, E. G. Gardner CL 
2011). 
Ability to use HS as an attachment factor however affects the assembly and 
release process of the virus particles. Due to the increased affinity of RRV-E2 
glycoproteins towards HS, envelope glycoproteins get retained along the secretory 
pathway, especially in the Golgi, since HS based glycosylation of other proteins takes 
place in the Golgi (DK 2011). Thus the envelope glycoproteins with basic amino-acid 
mutations are prevented from reaching the plasma membrane. Hence they are not 
efficiently incorporated into the budding pseudotyped virus. Secondly, even if the 
glycoproteins reach the plasma membrane and get incorporated into budding pseudotyped 
virus, the data indicate that their affinity towards HS prevents the release of virus particle 
from the cell surface. Studies done in Sindbis virus have shown that virus particles 
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utilizing HS had lesser viremia resulting in lower pathogenicity. This led to the reversion 
of virus particles adapted to utilize HS to that wild-type form that had reduced affinity 
towards HS. It was proposed that one reason for lesser viremia seen in Sindbis virus 
utilizing HS was decreased dissemination of the virus (G. D. Byrnes AP 2000). Similar 
studies in Venezuela equine encephalitis virus and Chikungunya virus show attenuation 
of HS-binding mutant viruses due to rapid clearance and decrease in the spread of virus 
particles (Bernard KA 2000, H. J. Gardner CL 2014). 
 This interaction between the HS-utilizing viruses and HS is reminiscent of the 
interaction between influenza virus and its attachment factor, sialic acid. Sialic acid 
facilitates the entry of influenza virus by attaching to the viral and increases their 
concentration on the cell surface (Skehel JJ 2000, Wagner R 2002). However, the same 
attachment factors, when expressed on the cells producing the virus particles, hinder the 
release of the viral particles from the cell surface (Wagner R 2002). The release of 
influenza virus from cell surfaces is facilitated by the Neuraminidase protein intrinsic to 
the virus, which cleaves the sialic acid (Air GM 1989, Bucher D 1975). Because such an 
intrinsic process for facilitating the release of virus particles is not present in our 
pseudotyped viral vector, one of our future goals is to develop a producer cell line that 
does not express HS for the production of this pseudotyped viral vector that utilizes HS 
as an attachment factor. A general principle arising from these studies is that altering 
producer cell membrane components may improve pseudotyped virus production through 
enhancing viral particle release. 
The attachment of viruses to cell-surface heparan sulfate has been proposed both 
to be an inherent component of viral entry in vivo and an adaptation to propagation in cell 
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culture.  An important consequence of our studies is the conclusion that utilization of 
heparan sulfate as an attachment factor can have deleterious effects on viral release either 
through intracellular retention of the heparan-sulfate-binding viral proteins or adsorption 
of the viral particles to producer cells. HSV-1 utilizes heparan sulfate as an attachment 
factor for infection of host cells (S. P. Shukla D 2001, L. J. Shukla D 1999). Recently it 
has been demonstrated that increased host heparinase expression is a consequence of 
herpes simplex virus-1 infection and that augmentation of heparinase expression 
correlates with enhanced HSV-1 release (Hadigal SR 2015). These data reinforce our 
conclusion that if a virus utilizes an ubiquitous and abundant cell component for entry 
then there must be a mechanism for release of the virus from an infected cell if efficient 
infection is to occur.  This issue is likely to be particularly critical when the utilization of 






CHAPTER 5. ROLE OF CHOLESTEROL IN ENTRY OF PSEUDOTYPES 





The tissue tropism of a virus can be modified by replacing the envelope-glycoproteins of 
that virus with those of other viruses, through the process of pseudotyping. Such 
pseudotyped viruses are good candidates as vectors for gene therapy/ transfer. In this 
study, we propose that retroviruses incorporating alphaviral glycoproteins will be suitable 
gene delivery vectors in Niemann Pick’s disease, type A (NPD-A). NPD-A is a genetic 
lipid-storage disorder characterized by severe deficiency of acid sphingomyelinase 
(ASMase), which results in excess accumulation of cholesterol and sphingolipids in the 
lysosomes and late endosomes. Previously it has been shown that cholesterol is required 
by alphaviruses for fusion process during the entry. We show that alphavirus-
glycoprotein retrovirus pseudotypes also require cholesterol for entry into the cells. 
Furthermore, excess cholesterol in cells facilitates the entry of alphavirus-glycoprotein 
retroviral pseudotypes. Alphavirus-glycoprotein pseudotypes transduce the acid 
sphingomyelinase deficient (ASMase-/-) cells derived from Niemann Pick’s disease-
model mice more efficiently than the cells from healthy mice (ASMase+/+). Thus 
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alphavirus-glycoprotein pseudotypes hold a potential as suitable vector for gene therapy/ 
transfer in NPD-A. 
5.2 Introduction 
Neimann Pick’ disease (NPD) is a lysosomal storage disease. Types A and B of 
this disease are caused by mutations in the SMPD1 gene, leading to severe deficiency of 
ASMase activity. Deficiency in this enzyme leads to excess accumulation of 
sphingolipids in lysosomes and late endosomes (Schuchman EH 2001). Accumulation of 
sphingolipids is coupled with the accumulation of cholesterol in lysosomes and 
endosomes (Puri V 1999, Choudhury A 2004). NPD-A is a more severe form this 
disease, than the other three types NPD-B, NPD-C and NPD-D. Clinical manifestations 
in NPD-A include persistent early jaundice, hepatosplenomegaly, enlarged abdomen, 
delay in developmental milestones, intellectual developmental disorders, stunted growth, 
hypotonia and rigidity (Crocker AC 1958). NPD-A has poor prognosis leading to an early 
death, usually by 2 to 4 years of age. Currently there is no cure available for this disease. 
However, gene transfer studies in cultured NPD cells as well as diseased-mouse models 
have shown to correct the metabolic defect (Suchi M 1992, Dodge JC 2005). 
Viruses are frequently used as gene therapy/ gene transfer vectors to introduce the 
gene of choice into cells. Since entry of an enveloped virus depends on its envelope 
proteins, the range of target cells that a virus can enter into can be modified by replacing 
the envelope glycoproteins of that virus with those of other viruses having the desired 
range of tissue tropism, through the process of pseudotyping (Sanders 2002). Such 
pseudotyped viruses are good candidates as vectors for gene therapy/transfer. Therapeutic 
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need would determine the choice of virus whose envelope glycoproteins need to be 
incorporated in the pseudotyped virus (Sanders 2002).  
Retroviruses are commonly used as gene delivery vectors because they allow 
stable transfer and efficient expression of the genetic material under the influence of their 
strong promoter. However, they have limited host range and tissue tropism.  With the 
purpose of broadening the tissue tropism and further enhancing the transduction 
efficiency of this virus, we pseudotyped Moloney Murine Leukemia Virus (MoMuLV), a 
model retrovirus, with envelope glycoproteins of Ross River Virus (RRV), an alphavirus 
(Sharkey CM 2001). Successful in vivo gene transfer studies have been conducted 
previously using lentiviral pseudotypes incorporating alphaviral envelope glycoproteins 
(Kang Y 2002).   
Alphaviruses are mosquito-borne viruses and are classified into Old World 
viruses, which include Ross River Virus (RRV), Sindbis Virus (SINV), Semliki Forest 
virus (SFV) and New World viruses, which include Venezuelan Equine Encephalitis 
virus (VEEV), Eastern Equine Encephalitis virus (EEEV) and Western Equine 
Encephalitis virus (WEEV). Alphaviruses have wide host-range and tissue tropism. 
Alphaviruses enter the cells via receptor-mediated endocytosis. Two of the alphaviral 
glycoproteins, E1 and E2 are required for this entry process (C.-V. C. Kielian MC 2010). 
The E2-glycoprotein is involved in the initial receptor-binding phase, whereas the E1 
glycoprotein is responsible for fusion of viral and cellular membranes (C.-V. C. Kielian 
MC 2010, Jose J 2009). Once the virus gets internalized, the acidic pH of endosomes 
leads to dissociation of the E1-E2 heterodimer exposing the hidden fusion loop of E1 (C.-
V. C. Kielian MC 2010). The insertion of fusion loop into the endosomal membrane 
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initiates the fusion process (C.-V. C. Kielian MC 2010). Studies in alphaviruses like 
Sindbis Virus (SINV) and Semliki Forest Virus (SFV) using liposomes show that 
cholesterol and sphingolipids are required for this step of fusion of the viral membrane 
with the cellular membrane (Helenius A 1984) (Nieva JL 1994). Micro-domains of 
cholesterol and sphingolipids are called lipid-rafts (Figure 5.1). These cholesterol-rich 
lipid rafts have also been shown to be required for glycoprotein transport and the exit 
process (G. D. Ng CG 2006, C. I. Ng CG 2008). Furthermore, studies have shown that 
SINV causes fatal encephalitis in knock-out mice deficient in acid sphingomyelinase 







Figure 5.1 Cholesterol and Sphingolipid rich lipid rafts 
 
  
Compartmentalization of lipid bilayer forms micro-domains called as ‘lipid rafts’ which 
are rich in cholesterol and sphingolipids content. The factors contributing to formation 
and stability of lipid rafts are hydrogen bonding between polar heads, interaction between 
long hydrophobic chains and complementarity between the shapes of lipid molecules. 
Various proteins are embedded within these lipid-rafts. 
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Alphaviruses mainly infect brain, liver, bones, muscles, lungs and reticulo-
endothelial tissue and these sites can be targeted using pseudotyped viruses incorporating 
alphaviral glycoproteins (Kang Y 2002). An overlap exists between the organs infected 
by alphaviruses and the organs that get affected in Niemann Pick’s Disease.  At the 
cellular level, the fusion process of alphaviruses, which requires cholesterol, takes place 
in endosomes. In NPD-A, accumulation of sphingolipids and cholesterol also takes place 
in endosomes and lysosomes (Puri V 1999, Choudhury A 2004). By incorporating the 
alphaviral glycoproteins in pseudotype system, we are trying to investigate if cholesterol 
can have an effect on transduction efficiency of MoMuLV pseudotyped with alphavirus 
envelope glycoproteins. We demonstrate that these pseudotyped viruses have higher 
transduction efficiency in Niemann Pick-Type A model cells. These pseudotypes thus 
hold a potential as vectors for gene transfer/therapy studies in Niemann Pick’s disease.  
5.3 Results 
5.3.1 Alphavirus-MoMuLV pseudotypes require cholesterol-rich lipid rafts for entry 
in mammalian cells 
Since the entry process of envelope forming virus in a pseudotyped virus can be studied 
in isolation, alphavirus-MoMuLV pseudotypes were used to determine if cholesterol-rich 
lipid rafts are required for cell entry. To show that lipid rafts are required for entry, the 
lipid-rafts in target cells (BHK and NIH3T3) were disrupted using cholesterol lowering 
drugs, namely lovastatin and ß-mCD. The experiment was also performed on cholesterol-
depleted cells, which were replenished with cholesterol. MoMuLV pseudotyped with 
MoMuLV glycoproteins was used as positive control (S. J. Lu X 2000), whereas 
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MoMuLV pseudotyped with Vesicular stomatitis virus glycoprotein was used as negative 
control (Yonezawa A 2005). 
The data shown in Figure 5.2A and Figure 5.2B suggest that, the transduction 
titers for pseudotypes with alphaviral glycoproteins are lower in cells treated with lipid-
lowering drugs as compared to non-treated cells. On replenishing the cells with 
cholesterol, higher values of transduction units/mL are obtained. No such difference is 
noted in transduction efficiency of pseudotypes incorporating VSV glycoproteins. Thus, 




















































Cells treated with Lovastatin and
mßCD
Repletion with Cholesterol
Supernatant media overlying producer ØNXnlslacZ cells containing the pseudotyped 
virus particles were passed through a 0.45 µm filter and 5 µg/mL of hexadimethrine 
bromide was added to these filtered media. These media were used to transduce target 
cells, NIH-3T3 (Figure 5.1A) and BHK (Figure 5.1B). Cholesterol depletion was 
achieved in target cells by incubating the target cells with cholesterol-lowering drugs, 
namely lovastatin and methyl-beta-cyclodextrin (ß-mCD). The transduced target cells 
were stained with X-gal and transduction titers were calculated. Results shown are 
averages ± SD of three independent assays. The values shown in the graph represent 
transduction titers in percentages, where 100% TU/mL for VSV, MoMuLV, RRV, SFV, 
SINV and VEEV pseudotypes are 15000, 15000, 15000, 13000, 16000, 11000 and 15000 
in NIH-3T3 cells, and 4000, 0, 5500, 5000,3500, 7000 in BHK cells respectively. The 
experiment was also performed following repletion of the cholesterol-depleted cells with 





5.3.2 Alphavirus-baculovirus pseudotypes require cholesterol for entry into insect 
cells 
To rule out any direct effect of lipid-lowering drugs on the transduction values, 
transduction assays were carried out in mosquito-derived C6/36 cells. The cholesterol 
content of these cells can be reduced to as low as 1- 2% of their actual value, when grown 
in sterol-free conditions (X. Y. Lu X 2002).  Since pseudotyped viruses grown from 
ØNXnlslacZ cells cannot transduce insect cells, baculovirus pseudotypes were produced. 
Baculovirus pseudotypes incorporating baculovirus glycoprotein, gp64 was used as 
positive control (Kataoka C 2001).The data show that transduction titers of these 
baculovirus pseudotyped viruses incorporating alphaviral glycoproteins are lower in cells 
grown in sterol-free condition as compared to cells not grown in sterol restricted 
conditions (Figure 5.3).  Repletion of cells grown in sterol-free conditions with 










5 µg/mL of hexadimethrine bromide was added to the filtered supernatant media 
overlying SF9 cells. These media containing the baculovirus pseudotypes were used to 
transduce target C6/36 cells grown in DMEM+10% FBS (a), cholesterol depleted media 
(b) and media replenished with cholesterol (c). Cholesterol depletion was achieved in 
C6/36 cells by growing these cells in sterol-free condition. Experiments were also 
performed in these cells after replenishing them with β-sterol by adding 50 µg/mL 
cholesterol. The transduced target cells were identified using the fluorescent microscopy 
and transduction titers were calculated. The experiments were repeated thrice and atleast 
10 fields (one field represented) were inspected per plate for each sample (Figure 5.2A). 
The graph shows averages±SD of transduction titers in percentages from three 
independent assays (Figure 5.2B), where100% TU/mL for Baculovirus, VSV and RRV 




   
   
   
































5.3.3 Alphavirus-MoMuLV pseudotypes transduce ASMase-/- cells more efficiently 
than ASMase+/+ cells 
 To see whether excess cholesterol facilitates the entry of these pseudotyped viruses into 
the cells, transduction assay was carried out in ASMase-/- cells and ASMase+/+ cells. 
Absence of acid sphingomyelinase leads to excess accumulating of sphingomyelin and 
cholesterol in the cells. Fluorometric assay confirmed that the cholesterol levels in 
ASMase-/- cells were higher than ASM+/+ cells (Figure 5.4B). The data show (Figure 
5.4A) that transduction efficiency of pseudotypes with alphaviral glycoproteins is higher 
in ASMase-/- cells than in ASMase+/+ cells while not much difference was noted in 































































Supernatant media overlying producer ØNXnlslacZ cells containing the pseudotyped 
virus particles were passed through a 0.45 µm filter. Hexadimethrine bromide (5 µg/mL) 
was added to these filtered media. These media were used to transduce target ASMase+/+ 
and ASMase-/- cells. The transduced target cells were stained with X-gal and 
transduction titers were calculated. Results shown are averages±SD of three independent 
assays represented in percentages (Figure 5.3A). The difference in the concentration of 
cholesterol in ASMase-/- and ASMase+/+ cells was verified using a fluorometric 






NPD-Type A is an autosomal recessive genetic disorder caused by mutation in 
SMPD1 gene and is characterized by excess accumulation of sphingolipids and 
cholesterol in the cells. The treatment is mainly symptomatic and there is no cure 
available for this disease. However, gene transfer studies performed using viral vectors 
have shown to correct the metabolic defect in cultured cells as well as mouse models 
(Suchi M 1992, Dodge JC 2005). 
In our earlier study, we produced a pseudotyped virus by replacing the envelope 
of Moloney Murine Leukemia Virus (MoMuLV) with the envelope of Ross River Virus 
(RRV). Pseudotyping helps us in combining features of retrovirus, that are ideal for gene 
transfer such as ability to allow fast and stable transfer of transgene to cells and efficient 
expression of the transgene for prolonged period of time under the influence of its strong 
promoter system, along with the features of alphaviruses which is to allow entry into 
wide range of cells. This makes these pseudotyped viruses a potential gene 
therapy/transfer vector in systemic genetic disorders. Successful in vivo gene transfer 
studies have been conducted using lentiviral pseudotypes incorporating alphaviral 
glycoproteins (Kang Y 2002). The cells specifically targeted by pseudotypes 
incorporating alphaviral glycoproteins are neuronal cells, neuroglia, hepatocytes, Kupffer 
cells and reticulo-endothelial cells (Kang Y 2002). Modest transductions are also seen in 
myocytes and airway epithelial cell (Kang Y 2002). Interestingly, the tissues targeted by 
the pseudotypes with alphaviral glycoproteins are similar to the ones affected in NPD-A 
(Hua G 2013).  
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Since the entry of the virus depends on the envelope of the virus, the pseudotyped 
virus has the entry mechanism similar to that of envelope forming virus and this entry 
mechanism can be studied in isolation using the pseudotyped system. Using lipid-
lowering drugs and sterol-free conditions to grow cells, we show that pseudotypes 
incorporating alphaviral glycoproteins require cholesterol for entry into the cells just like 
wild-type alphaviruses. Studies in alphaviruses have shown that ASMase-/- mice were 
more susceptible to fatal encephalitis (G. D. Ng CG 2006). Studies done in human NPD 
cells which lacked ASMase enzyme attributed the higher virulence to rapid replication of 
the virus in ASMase deficient cells and to production of more infectious viral particles 
from these cells (C. I. Ng CG 2008). Here, using pseudotyped viruses, in which entry of 
the envelope forming virus can be exclusively studied in isolation, we show that the 
excess cholesterol in these cells facilitates the entry of pseudotyped viruses incorporating 
alphaviral glycoproteins. Thus, efficient entry in ASMases deficient cells could be 
another factor responsible for higher virulence and pathogenicity of alphaviruses in these 
cells. 
These characteristics make pseudotyped viruses incorporating alphaviral 
glycoproteins suitable vectors for gene transfer/therapy in NPD-A. Further studies using 
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